REDWOOD CITY, Calif., Nov. 9, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced additional meetings to its Fall conference presentation schedule. The Company will present at the following conferences:
The 16th Annual Connective Tissue Oncology Society (CTOS) Meeting taking place in Paris, France. On November 11th, a poster session will take place that will update the clinical data from the 403 trial, which is investigating TH-302 in combination with doxorubicin in patients with soft tissue sarcoma who have not received prior doxorubicin. Copies of the poster may be obtained by calling the Company.
Wall Street Analyst Forum 21st Annual Analyst Conference taking place in New York City. On November 11th at 10:35 a.m. ET, Dr. Charles Hart, Threshold's Vice President Biology will present a corporate overview.
Lazard Capital Markets 7th Annual Healthcare Conference taking place in New York City. On November 16th at 10:55 a.m. ET, Dr. Barry Selick, Threshold's chief executive officer will present a corporate overview.
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website ().
CONTACT: Threshold Pharmaceuticals, Inc. Denise Powell, Sr. Director, Corporate Communications 650-474-8206 dpowell@thresholdpharm.com